×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Books
Maps
Videos
Shopping
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
The Globe and Mail
Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.
22 hours ago
Inventiva pauses MASH study over patient's raised liver enzymes
Fierce Biotech
Inventiva has paused enrolling new patients into a phase 3 trial of its lead liver disease drug after a participant experienced raised...
2 months ago
Inventiva halt recruitment for Phase III NASH trial following adverse event
Clinical Trials Arena
Inventiva has paused enrolment for Phase III trial investigating lanifibranor in NASH after a serious adverse event was seen in a patient.
2 months ago
Inventiva Pauses Late-Stage NASH Trial, Keeps Field Open for Madrigal
BioSpace
Following a patient case of severe liver enzyme elevations, Inventiva is suspending its Phase III NATiV3 study in non-alcoholic...
2 months ago
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
Yahoo Finance
Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage...
1 month ago
Inventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Event
MarketWatch
By Will Feuer Shares of Inventiva tumbled in premarket trading in New York after the biopharmaceutical company said it has paused the...
2 months ago
Adverse event halts Inventiva's pivotal lanifibranor NASH trial
BioWorld MedTech
Inventiva SA has halted enrollment in its pivotal phase III Nativ3 trial with nonalcoholic steatohepatitis (NASH) candidate lanifibranor...
2 months ago
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients ...
GlobeNewswire
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult...
1 month ago
Inventiva Phase 2 study for MASH drug meets primary endpoint (NASDAQ:IVA)
Seeking Alpha
Inventiva (IVA) reported a Phase 2 study of its drug lanifibranor met its primary efficacy endpoint in the treatment of patients with...
1 month ago